Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.39 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.38 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.35 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15853672 | 0.98 | CYP1A2 (0.42) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| SCHEMBL22917833 | 0.98 | CYP1A2 (0.42) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| Hydrochloric Acid SCHEMBL23499905 | 0.94 | HSD17B10 (0.39) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| SCHEMBL23514429 | 0.92 | HSD17B10 (0.40) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| Hydrochloric Acid SCHEMBL3402044 | 0.81 | CYP1A2 (0.43) | CYP1A2TDP1HSD17B10CHRM1MGLL | |
| Hydrochloric Acid SCHEMBL29999746 | 0.81 | HRH3 (0.32) | DPP4 | |
| SCHEMBL15853678 | 0.81 | DPP7 (0.41) | DPP4 | |
| SCHEMBL15853681 | 0.79 | DPP7 (0.43) | DPP4 | |
| SCHEMBL8975358 | 0.79 | DPP7 (0.43) | DPP4 | |
| SCHEMBL16197319 | 0.79 | CYP1A2 (0.45) | CYP1A2TDP1HSD17B10CHRM1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486241-B2 | Cystine diamide analogs for cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-12-02 | — | — | US | disclosed |
| US-12391661-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4072537-A1 | CYSTINE DIAMIDE ANALOGS FOR CYSTINURIA | Rutgers, the State University of New Jersey (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-115103669-A | Cystine diamide analogs for cystinuria | 新泽西鲁特格斯州立大学 | 2022-09-23 | — | — | CN | disclosed |
| US-11420949-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486241-B2 | Cystine diamide analogs for cystinuria | CTH, CBS, SLC7A11 | CHRM1 3121/4885HTR1A 2608/4885DPP4 1103/4885 |
| US-11420949-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | CTH, CBS, SLC6A12 | CHRM1 908/4885HTR1A 2188/4885DPP4 3444/4885 |
| US-12391661-B2 | Cystine diamide analogs for the prevention of cystine stone formation in cystinuria | CTH, CBS, SLC6A12 | CHRM1 908/4885HTR1A 2188/4885DPP4 3444/4885 |
| US-20230002337-A1 | CYSTINE DIAMIDE ANALOGS FOR THE PREVENTION OF CYSTINE STONE FORMATION IN CYSTINURIA | CTH, CBS, SLC6A12 | CHRM1 908/4885HTR1A 2188/4885DPP4 3444/4885 |
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | CTH, CBS, SLC7A11 | CHRM1 3121/4885HTR1A 2608/4885DPP4 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.